<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

LNCaP clone FGC

Description

LNCaP clone FGC (Prostate Cancer CDX Model) 

The LNCaP clone FGC line was derived from a lymph node metastasis of human prostate carcinoma. It is androgen-sensitive, expressing functional androgen receptors. LNCaP cells also produce prostate-specific antigen (PSA), aligning with clinical biomarkers. This makes it a valuable model for early and androgen-responsive prostate cancer research. 

Key Features: 

  • Derived from lymph node metastasis of prostate cancer. 
  • Androgen receptor–positive. 
  • Produces PSA. 
  • Useful in hormone-dependent prostate cancer studies. 

Applications: 
LNCaP is applied in studies of androgen receptor biology and therapeutic response. It supports biomarker validation, including PSA monitoring. Researchers use it to evaluate anti-androgen and hormonal therapies. Its androgen sensitivity makes it highly relevant for translational prostate cancer pipelines.

Details
Tumor Type
Prostate
Tumor Subtype
Prostate Carcinoma (derived from lymph node)
Organism
Human
Mouse Sex
Male
Mouse Strain
NOG
Mutated Genes
ABL1
Mutation: p.N770S
Effect: Missense Variant
APC
Mutation: p.R2714C
Effect: Missense Variant
Impact: Uncertain Significance
AR
Mutation: p.T878A
Effect: Missense Variant
Impact: Pathogenic
ARID1A
Mutation: p.G285EfsTer78
Effect: Frameshift Variant
ARID1B
Mutation: p.E2287Ter
Effect: Stop-Gain
ATRX
Mutation: p.E2265del
Effect: Inframe Deletion
TERT
Mutation: p.R865C
Effect: Missense Variant
Impact: Likely Pathogenic & Uncertain Significance
*Data provided by DepMap
Lumin Data
RNASeq WES
Expression Data
Growth Curve
View on Lumin